Opinion|Videos|June 21, 2024
Examining Key Data from the FLAURA2 and MIRAPOSA Trials
A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.
Advertisement
Episodes in this series
- Recently, efficacy and safety data from the phase 3
FLAURA2 trial were published regarding the use of osimertinib alongside chemotherapy in the front-line setting. What are some important points to note from this study, and which patients might benefit from adding chemotherapy to osimertinib?- Please include a discussion of both PFS and OS observed in the FLAURA2 study
- Please discuss the adverse events observed in the monotherapy versus combination therapy group.
- The combination of amivantamab and a new 3rd generation EGFR TKI, lazertinib, had new front-line data presented at ESMO 2023, namely the
MARIPOSA trial. How was this study designed? - What were the results of the MARIPOSA trial, including efficacy and safety data, and how do you anticipate this data to ultimately impact front-line management of EGFR+ metastatic NSCLC with Ex19del or Ex21 L858R mutations?
- Despite FLAURA2 and MARIPOSA data now, what questions remain unanswered in the front-line management?
- How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?
Advertisement
Related to this article
This update came with no changes to the safety sections of labeling, with no new signals identified with longer follow-up.
The update shortens required observation to 6 to 8 hours from 22 to 24, easing tarlatamab administration in community settings for ES-SCLC.
A prospective observational study found microplastics more frequently and at higher levels in lung samples from patients with lung malignancies, although the findings do not establish that the particles cause cancer.
Eight-year phase 3 ADAURA trial data show adjuvant osimertinib boosts survival in patients with resected EGFR-mutant NSCLC.
Phase 3 HARMONi-2 interim analysis shows first bispecific PD-1/VEGF antibody outperforming standard immunotherapy in first-line NSCLC.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
Biologic Stewardship: The Next Frontier for Health System Pharmacists
5